Latest News and Press Releases
Want to stay updated on the latest news?
-
PASADENA, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that more than 25 of its scientists and...
-
Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following...
-
- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector® Provides Targeted and Compartmentalized Delivery of Therapeutics...
-
New York, Jan. 23, 2025 (GLOBE NEWSWIRE) -- A groundbreaking study published in the January edition of Translational Vision Science & Technology, an ARVO journal, reveals that individuals with...
-
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
-
Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.
-
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...
-
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
-
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
-
Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies,...